{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:20:31Z","timestamp":1770139231908,"version":"3.49.0"},"reference-count":9,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,11,2]]},"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>Imatinib is used to treat several haematological and solid malignancies. Cutaneous side effects could often limit the use of this medication. We present a case of a 62-year-old woman with a history of a gastrointestinal stromal tumour that developed a delayed cutaneous adverse reaction 10 days after starting imatinib 400\u2009mg daily. She developed the same symptoms with reintroduction at a dose of 100\u2009mg and with an alternative tyrosine kinase inhibitor, nilotinib 50\u2009mg\/day. Given that imatinib was considered her best treatment, she underwent a long induction of drug tolerance (IDT) protocol to imatinib. Patient tolerated the medication without further reactions for 6\u2009months and had improvement of her cancer per last imaging studies. IDT should be considered in delayed hypersensitivity reactions to imatinib after a failed reintroduction of the drug or when no other equally effective agents are available.<\/jats:p>","DOI":"10.1136\/bcr-2020-237069","type":"journal-article","created":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T23:30:38Z","timestamp":1607902238000},"page":"e237069","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Long induction of tolerance to imatinib"],"prefix":"10.1136","volume":"13","author":[{"given":"Leyla","family":"Bojanini","sequence":"first","affiliation":[{"name":"Medicine, Mayo Clinic, Jacksonville, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Attia","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Mayo Clinic, Jacksonville, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haesuk","family":"Heagney","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic, Jacksonville, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5754-6130","authenticated-orcid":false,"given":"Alexei","family":"Gonzalez-Estrada","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic, Jacksonville, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,12,13]]},"reference":[{"key":"2025082713262116000_13.12.e237069.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2015.04.022"},{"key":"2025082713262116000_13.12.e237069.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2010.08.002"},{"key":"2025082713262116000_13.12.e237069.3","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.anai.2016.08.035","article-title":"Slow desensitization of imatinib-induced nonimmediate reactions and dynamic changes of drug-specific CD4+CD25+CD134+ lymphocytes","volume":"117","author":"Klaewsongkram","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025082713262116000_13.12.e237069.4","first-page":"345","article-title":"Successful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literature","volume":"25","author":"Park","year":"2004","journal-title":"Allergy Asthma Proc"},{"key":"2025082713262116000_13.12.e237069.5","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/CAD.0000000000000669","article-title":"Imatinib-Induced drug reaction with eosinophilia and systemic symptoms in solid tumors: a patient with dermatofibrosarcoma protuberans and successful desensitization management","volume":"29","author":"Ben-Ami","year":"2018","journal-title":"Anticancer Drugs"},{"key":"2025082713262116000_13.12.e237069.6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1081-1206(10)60016-6","article-title":"Desensitization to imatinib in patients with leukemia","volume":"97","author":"Nelson","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025082713262116000_13.12.e237069.7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.18176\/jiaci.0304","article-title":"Hypersensitivity to imatinib: successful desensitization in a skin test-positive patient","volume":"28","author":"Penza","year":"2018","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2025082713262116000_13.12.e237069.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.09.009"},{"key":"2025082713262116000_13.12.e237069.9","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jaip.2018.07.031","article-title":"A large Single-Hospital experience using drug provocation testing and rapid drug desensitization in hypersensitivity to antineoplastic and biological agents","volume":"7","author":"Madrigal-Burgaleta","year":"2019","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-237069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T20:26:30Z","timestamp":1756326390000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-237069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":9,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,13]]},"published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1136\/bcr-2020-237069"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-237069","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}